cold and clammy; breathing problems especially at night; hot at injection site; Severe itching at injection site; Rash in right hand at injection site; Swelling at injection site; Redness at injection site; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of COLD SWEAT (cold and clammy), DYSPNOEA (breathing problems especially at night), VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PRURITUS (Severe itching at injection site) and VACCINATION SITE RASH (Rash in right hand at injection site) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product METOPROLOL SUCCINATE for an unknown indication.    The patient's past medical history included Cardiac dysfunction (Cardiac problems) since an unknown date. Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID], PREGABALIN (LYRICA), METFORMIN, INSULIN GLARGINE (LANTUS), INSULIN ASPART (NOVOLOG), LEVOTHYROXINE, VITAMIN D3, FISH OIL, CENTRUM SILVER ADULTS 50+, OMEPRAZOLE and OXYCODONE for an unknown indication.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started METOPROLOL SUCCINATE (unknown route) at an unspecified dose. On 04-Apr-2021, the patient experienced VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PRURITUS (Severe itching at injection site), VACCINATION SITE RASH (Rash in right hand at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site). On an unknown date, the patient experienced COLD SWEAT (cold and clammy) and DYSPNOEA (breathing problems especially at night). On 08-Apr-2021, VACCINATION SITE PRURITUS (Severe itching at injection site), VACCINATION SITE RASH (Rash in right hand at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) had resolved. At the time of the report, COLD SWEAT (cold and clammy), DYSPNOEA (breathing problems especially at night) and VACCINATION SITE WARMTH (hot at injection site) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: normal. On an unknown date, Chest X-ray: normal. On an unknown date, Heart rate: normal. On an unknown date, Troponin: normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient visited his physician for the reported events.   No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 14-Apr-2021 and was forwarded to Moderna on 14-Apr-2021.    This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of COLD SWEAT (cold and clammy), DYSPNOEA (breathing problems especially at night), VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PRURITUS (Severe itching at injection site) and VACCINATION SITE RASH (Rash in right hand at injection site) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product METOPROLOL SUCCINATE for an unknown indication.    The patient's past medical history included Cardiac dysfunction (Cardiac problems) since an unknown date. Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID], PREGABALIN (LYRICA), METFORMIN, INSULIN GLARGINE (LANTUS), INSULIN ASPART (NOVOLOG), LEVOTHYROXINE, VITAMIN D3, FISH OIL, CENTRUM SILVER ADULTS 50+, OMEPRAZOLE and OXYCODONE for an unknown indication.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started METOPROLOL SUCCINATE (unknown route) at an unspecified dose. On 04-Apr-2021, the patient experienced VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PRURITUS (Severe itching at injection site), VACCINATION SITE RASH (Rash in right hand at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site). On an unknown date, the patient experienced COLD SWEAT (cold and clammy) and DYSPNOEA (breathing problems especially at night). On 08-Apr-2021, VACCINATION SITE PRURITUS (Severe itching at injection site), VACCINATION SITE RASH (Rash in right hand at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) had resolved. At the time of the report, COLD SWEAT (cold and clammy), DYSPNOEA (breathing problems especially at night) and VACCINATION SITE WARMTH (hot at injection site) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: normal. On an unknown date, Chest X-ray: normal. On an unknown date, Heart rate: normal. On an unknown date, Troponin: normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient visited his physician for the reported events.   No Treatment information for the event was provided.